PMID- 38033651
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231202
IS  - 2213-4220 (Print)
IS  - 2213-4239 (Electronic)
IS  - 2213-4220 (Linking)
VI  - 12
IP  - 4
DP  - 2023 Dec
TI  - Chinese herbal injections in combination with radiotherapy for advanced 
      pancreatic cancer: A systematic review and network meta-analysis.
PG  - 101004
LID - 10.1016/j.imr.2023.101004 [doi]
LID - 101004
AB  - BACKGROUND: Advanced pancreatic cancer (APC) is a fatal disease with limited 
      treatment options. This study aims to evaluate the effectiveness and safety of 
      different Chinese herbal injections (CHIs) as adjuvants for radiotherapy (RT) in 
      APC and compare their treatment potentials using network meta-analysis. METHODS: 
      We systematically searched three English and four Chinese databases for 
      randomized controlled trials (RCTs) from inception to July 25, 2023. The primary 
      outcome was the objective response rate (ORR). Secondary outcomes included 
      Karnofsky performance status (KPS) score, overall survival (OS), and adverse 
      events (AEs). The treatment potentials of different CHIs were ranked using the 
      surface under the cumulative ranking curve (SUCRA). The Cochrane RoB 2 tool and 
      CINeMA were used for quality assessment and evidence grading. RESULTS: Eighteen 
      RCTs involving 1199 patients were included. Five CHIs were evaluated. Compound 
      Kushen injection (CKI) combined with RT significantly improved ORR compared to RT 
      alone (RR 1.49, 95 % CrI 1.21-1.86). Kanglaite (KLT) plus RT (RR 1.58, 95 % CrI 
      1.20-2.16) and CKI plus RT (RR 1.49, 95 % CrI 1.16-1.95) were associated with 
      improved KPS score compared to radiation monotherapy, with KLT+RT being the 
      highest rank (SUCRA 72.28 %). Regarding AEs, CKI plus RT was the most favorable 
      in reducing the incidence of leukopenia (SUCRA 90.37 %) and nausea/vomiting 
      (SUCRA 85.79 %). CONCLUSIONS: CKI may be the optimal choice of CHIs to combine 
      with RT for APC as it may improve clinical response, quality of life, and reduce 
      AEs. High-quality trials are necessary to establish a robust body of evidence. 
      PROTOCOL REGISTRATION: PROSPERO, CRD42023396828.
CI  - (c) 2023 Korea Institute of Oriental Medicine. Published by Elsevier B.V.
FAU - Chen, Yun-Ru
AU  - Chen YR
AD  - Centre for Evidence-based Chinese Medicine, School of Traditional Chinese 
      Medicine, Beijing University of Chinese Medicine, Beijing, China.
FAU - Zhao, Ruo-Tong
AU  - Zhao RT
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, 
      Beijing, China.
FAU - Xu, Yi-Fang
AU  - Xu YF
AD  - Department of Oncology, Hubei Provincial Hospital of Traditional Chinese 
      Medicine, Wuhan, China.
FAU - Ma, Yin-Jie
AU  - Ma YJ
AD  - Wangjing Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing, 
      China.
FAU - Hu, Shao-Bo
AU  - Hu SB
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
AD  - Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, 
      China.
FAU - Wang, Xue-Hui
AU  - Wang XH
AD  - Centre for Evidence-based Chinese Medicine, School of Traditional Chinese 
      Medicine, Beijing University of Chinese Medicine, Beijing, China.
FAU - Fan, Bing-Bing
AU  - Fan BB
AD  - Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 
      University of Chinese Medicine, Beijing, China.
FAU - Zhou, Yan-Ji
AU  - Zhou YJ
AD  - Health Management Department, Aerospace Center Hospital, Beijing, China.
FAU - Huang, Yu-Bei
AU  - Huang YB
AD  - Department of Epidemiology and Biostatistics, National Clinical Research Center 
      of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin 
      Medical University Cancer Institute and Hospital, Tianjin, China.
FAU - Robinson, Nicola
AU  - Robinson N
AD  - Centre for Evidence-based Chinese Medicine, School of Traditional Chinese 
      Medicine, Beijing University of Chinese Medicine, Beijing, China.
AD  - School of Health and Social Care, London South Bank University, London, UK.
FAU - Liu, Jian-Ping
AU  - Liu JP
AD  - Centre for Evidence-based Chinese Medicine, School of Traditional Chinese 
      Medicine, Beijing University of Chinese Medicine, Beijing, China.
FAU - Liu, Zhao-Lan
AU  - Liu ZL
AD  - Centre for Evidence-based Chinese Medicine, School of Traditional Chinese 
      Medicine, Beijing University of Chinese Medicine, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231028
PL  - Netherlands
TA  - Integr Med Res
JT  - Integrative medicine research
JID - 101612707
PMC - PMC10681939
OTO - NOTNLM
OT  - Bayesian network meta-analysis
OT  - Compound Kushen injection
OT  - Integrative therapy
OT  - Pancreatic cancer
OT  - Radiotherapy
EDAT- 2023/11/30 18:45
MHDA- 2023/11/30 18:46
PMCR- 2023/10/28
CRDT- 2023/11/30 17:21
PHST- 2023/07/25 00:00 [received]
PHST- 2023/10/22 00:00 [revised]
PHST- 2023/10/25 00:00 [accepted]
PHST- 2023/11/30 18:46 [medline]
PHST- 2023/11/30 18:45 [pubmed]
PHST- 2023/11/30 17:21 [entrez]
PHST- 2023/10/28 00:00 [pmc-release]
AID - S2213-4220(23)00083-5 [pii]
AID - 101004 [pii]
AID - 10.1016/j.imr.2023.101004 [doi]
PST - ppublish
SO  - Integr Med Res. 2023 Dec;12(4):101004. doi: 10.1016/j.imr.2023.101004. Epub 2023 
      Oct 28.